By Professor Michael Leonard Friedlander

Journal articles

Solomon HJ; Atkinson KH; Coppleson JVM; Elliott PM; Houghton CRS; Murray J; Tattersall MHN; Friedlander ML; Green D, 1988, 'Ovarian carcinoma: Abdominopelvic irradiation following reexploration', Gynecologic Oncology, 31, pp. 396 - 401, http://dx.doi.org/10.1016/S0090-8258(88)80023-4

Friedlander ML; Hedley DW; Swanson C; Russell P, 1988, 'Prediction of long-term survival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer', Journal of Clinical Oncology, 6, pp. 282 - 290, http://dx.doi.org/10.1200/JCO.1988.6.2.282

FRIEDLANDER M; SHALEV R; GANOR T; STRIMLING S; BENAMOTZ A; KLAR H; WAX Y, 1987, 'SEASONAL FLUCTUATIONS OF GROWTH-RATE AND CHEMICAL-COMPOSITION OF GRACILARIA CF CONFERTA IN OUTDOOR CULTURE IN ISRAEL', HYDROBIOLOGIA, 151, pp. 501 - 507, http://dx.doi.org/10.1007/BF00046174

Trebeck CE; Friedlander ML; Russell P; Baird PJ, 1987, 'Brenner tumours of the ovary: A study of the histology, immunohistochemistry and cellular dna content in benign, borderline and malignant ovarian tumours', Pathology, 19, pp. 241 - 246, http://dx.doi.org/10.3109/00313028709066557

KIRSTEN F; ATKINSON KH; COPPLESON JVM; ELLIOTT PM; GREEN D; HOUGHTON R; MURRAY JC; RUSSELL P; SOLOMON HJ; FRIEDLANDER M; SWANSON CE; TATTERSALL MHN, 1987, 'Combination chemotherapy followed by surgery or radiotherapy in patients with locally advanced cervical cancer', BJOG an International Journal of Obstetrics Gynaecology, 94, pp. 583 - 588, http://dx.doi.org/10.1111/j.1471-0528.1987.tb03154.x

Zalcberg JR; Friedlander ML; Minden MD, 1986, 'Molecular evidence for the clonal origin of blast crisis in chronic myeloid leukaemia', British Journal of Cancer, 53, pp. 459 - 464, http://dx.doi.org/10.1038/bjc.1986.73

Friedlander M; Zalcberg J; Patterson B; Minden M; Bergsagel DE, 1985, 'APPARENT T-CELL NEOPLASMS WITH IMMUNOGLOBULIN GENE REARRANGEMENTS', Lancet, 326, pp. 670, http://dx.doi.org/10.1016/S0140-6736(85)90036-4

Taylor IW; Slowiaczek P; Friedlander ML; Tattersall MHN, 1985, 'Selective Toxicity of a New Lipophilic Antifolate, BW301U, for Methotrexate-resistant Cells with Reduced Drug Uptake', Cancer Research, 45, pp. 978 - 982

Hedley DW; Friedlander ML; Taylor IW, 1985, 'Application of DNA flow cytometry to paraffin‐embedded archival material for the study of aneuploidy and its clinical significance', Cytometry, 6, pp. 327 - 333, http://dx.doi.org/10.1002/cyto.990060409

Eckstein RP; Russell P; Friedlander ML; Tattersall MHN; Bradfield A, 1985, 'Metastasizing placental site trophoblastic tumor: A case study', Human Pathology, 16, pp. 632 - 636, http://dx.doi.org/10.1016/S0046-8177(85)80114-3

Friedlander ML; Russell P; Taylor IW; Tattersall MHN, 1985, 'Ovarian tumour xenografts in the study of the biology of human epithelial ovarian cancer', British Journal of Cancer, 51, pp. 319 - 333, http://dx.doi.org/10.1038/bjc.1985.44

Friedlander M; Foo MS; Quinn M, 1985, 'Relationship of steroid receptors and tumor ploidy in epithelial ovarian cancer', Proceedings of the American Association for Cancer Research, VOL. 26

Friedlander ML; Taylor IW; Russell P; Tattersall MH, 1984, 'Cellular DNA content—a stable feature in epithelial ovarian cancer', British Journal of Cancer, 49, pp. 173 - 179, http://dx.doi.org/10.1038/bjc.1984.29

Friedlander ML; Hedley DW; Taylor IW, 1984, 'Clinical and biological significance of aneuploidy in human tumours', Journal of Clinical Pathology, 37, pp. 961 - 974, http://dx.doi.org/10.1136/jcp.37.9.961

Hedley DW; Friedlander ML; Taylor IW; Rugg CA; Musgrove EA, 1984, 'DNA flow cytometry of paraffin‐embedded tissue', Cytometry, 5, pp. 660 - 660, http://dx.doi.org/10.1002/cyto.990050618

Friedlander ML; Russell P; Taylor IW; Hedley DW; Tattersall MHN, 1984, 'Flow cytometric analysis of cellular DNA content as an adjunct to the diagnosis of ovarian tumours of borderline malignancy', Pathology, 16, pp. 301 - 306, http://dx.doi.org/10.3109/00313028409068541

Hedley DW; Taylor IW; Coates AS; Tattersall MHN; Russell P; Friedlander ML, 1984, 'Influence of Cellular DNA Content on Survival in Advanced Ovarian Cancer', Cancer Research, 44, pp. 397 - 400

Friedlander ML, 1984, 'Prognostic Variables in Epithelial Ovarian Cancer: A Review', Australian and New Zealand Journal of Obstetrics and Gynaecology, 24, pp. 256 - 261, http://dx.doi.org/10.1111/j.1479-828X.1984.tb01506.x

Friedlander ML; Atkinson K; Coppleson JVM; Elliot P; Green D; Houghton R; Solomon HJ; Russell P; Tattersall MHN, 1984, 'The integration of chemotherapy into the management of locally advanced cervical cancer: A pilot study', Gynecologic Oncology, 19, pp. 1 - 7, http://dx.doi.org/10.1016/0090-8258(84)90150-1

FRIEDLANDER M; ZELIKOVITCH N, 1984, 'GROWTH-RATES, PHYCOCOLLOID YIELD AND QUALITY OF THE RED SEAWEEDS, GRACILARIA SP, PTEROCLADIA-CAPILLACEA, HYPNEA-MUSCIFORMIS, AND HYPNEA-CORNUTA, IN FIELD STUDIES IN ISRAEL', AQUACULTURE, 40, pp. 57 - 66, http://dx.doi.org/10.1016/0044-8486(84)90216-3

FRIEDLANDER M; DAWES CJ, 1984, 'STUDIES ON SPORE RELEASE AND SPORELING GROWTH FROM CARPOSPORES OF GRACILARIA-FOLIIFERA (FORSSKAL) BORGESEN VAR ANGUSTISSIMA (HARVEY) TAYLOR .1. GROWTH-RESPONSES', AQUATIC BOTANY, 19, pp. 221 - 232, http://dx.doi.org/10.1016/0304-3770(84)90040-8

FRIEDLANDER M; DAWES CJ, 1984, 'STUDIES ON SPORE RELEASE AND SPORELING GROWTH FROM CARPOSPORES OF GRACILARIA-FOLIIFERA (FORSSKAL) BORGESEN VAR ANGUSTISSIMA (HARVEY) TAYLOR .2. PHOTOSYNTHETIC AND RESPIRATORY RESPONSES', AQUATIC BOTANY, 19, pp. 233 - 241, http://dx.doi.org/10.1016/0304-3770(84)90041-X

Friedlander ML; Sims K; Kearsley JH, 1983, 'IMPAIRMENT OF RECALL IMPROVES TOLERANCE OF CYTOTOXIC CHEMOTHERAPY', Lancet, 322, pp. 686, http://dx.doi.org/10.1016/S0140-6736(83)92568-0

Friedlander M; Kaye SB; Sullivan A; Atkinson K; Elliott P; Coppleson M; Houghton R; Solomon J; Green D; Russell P; Hudson CN; Langlands AO; Tattersall MHN, 1983, 'Cervical carcinoma: A drug-responsive tumor-experience with combined cisplatin, vinblastine, and bleomycin therapy', Gynecologic Oncology, 16, pp. 275 - 281, http://dx.doi.org/10.1016/0090-8258(83)90102-6

FRIEDLANDER ML; KEARSLEY JH; SIMS K; COATES A; HEDLEY D; RAGHAVAN D; FOX RM; TATTERSALL MHN, 1983, 'LORAZEPAM AS AN ADJUNCT TO ANTIEMETIC THERAPY WITH HALOPERIDOL IN PATIENTS RECEIVING CYTOTOXIC CHEMOTHERAPY', Australian and New Zealand Journal of Medicine, 13, pp. 53 - 56, http://dx.doi.org/10.1111/j.1445-5994.1983.tb04550.x

, 1983, 'Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry', Journal of Histochemistry and Cytochemistry, 31, pp. 1333 - 1335, http://dx.doi.org/10.1177/31.11.6619538

Friedlander ML; Taylor IW; Russell P; Musgrove EA; Hedley DH; Tattersall MHN, 1983, 'Ploidy as a prognostic factor in ovarian cancer', International Journal of Gynecological Pathology, 2, pp. 55 - 63, http://dx.doi.org/10.1097/00004347-198301000-00005

Taylor IW; Musgrove EA; Friedlander ML; Foo MS; Hedley DW, 1983, 'The influence of age on the DNA ploidy levels of breast tumours', European Journal of Cancer and Clinical Oncology, 19, pp. 623 - 628, http://dx.doi.org/10.1016/0277-5379(83)90178-5

Tattersall MH; Friedlander ML, 1982, 'Cost considerations in cancer chemotherapy.', Australian Health Review A Publication of the Australian Hospital Association, 5, pp. 21 - 24

Friedlander ML; Tattersall MHN, 1982, 'Counting the costs of cancer therapy', European Journal of Cancer and Clinical Oncology, 18, pp. 1237 - 1241, http://dx.doi.org/10.1016/0277-5379(82)90124-9

Raghavan D; Coates A; Friedlander M, 1982, 'Mitoxantrone (XAN): Progress in a phase ii trial in Sydney, Australia', Proceedings of the American Society of Clinical Oncology, Vol. 1

Friedlander ML; Halley JBW; Sinosich MJ; Coates A, 1982, 'Pulmonary Pseudotumours Following Chemotherapy for Endodermal Sinus Tumour of the Ovary', Australian and New Zealand Journal of Obstetrics and Gynaecology, 22, pp. 110 - 112, http://dx.doi.org/10.1111/j.1479-828X.1982.tb01417.x

Friedlander M; Tattersall MHN, 1981, 'Postoperative radiotherapy in breast cancer', British Medical Journal Clinical Research Ed, 282, pp. 2133 - 2134, http://dx.doi.org/10.1136/bmj.282.6282.2133-d

Friedlander M; Kearsley JH; Tattersall MHN, 1981, 'ORAL LORAZEPAM TO IMPROVE TOLERANCE OF CYTOTOXIC THERAPY', Lancet, 317, pp. 1316 - 1317, http://dx.doi.org/10.1016/S0140-6736(81)92489-2

Friedlander ML, 1980, 'AMINOGLUTETHIMIDE AND PROSTATIC CANCER', Lancet, 316, pp. 1373, http://dx.doi.org/10.1016/S0140-6736(80)92440-X

FRIEDLANDER ML, 1980, 'AMINOGLUTETHIMIDE AND PROSTATIC-CANCER', LANCET, 2, pp. 1373 - 1373, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1980KU80600049&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers

Naidoo M; Mcnally O; Scott C; Friedlander M; Cohen P; Perera S; Brand A; Richardson G; Bunting M; Mohan R; Oehler M; Hyde S; Jobling T; Farrell R; Evans S; Rome R; Zalcberg J, 2024, 'EV306/#612  Patterns of ovarian cancer care and overall survival in Australia: a prospective study from the National Gynae-Oncology Registry (NGOR)', in E-Poster Viewing Abstracts, BMJ Publishing Group Ltd, pp. A240.1 - A240, presented at IGCS 2024 Annual Meeting Abstracts, http://dx.doi.org/10.1136/ijgc-2024-igcs.425

Werner B; Sjoquist KM; Espinoza D; Yip S; Chang G; Cummins MM; Mileshkin LR; Ananda S; Shannon CM; Friedlander M; Warton K; Ford C, 2023, 'Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response: A translational sub-study of the REZOLVE (ANZGOG-1101) clinical trial', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2023 - 06 June 2023

Yeung N; Lin H-M; Timmins H; Li T; Goldstein D; Friedlander M; Harrison ML; Mahon KL; Meikle P; Park S; Horvath L, 2023, 'Plasma lipidomic profiling of chemotherapy-induced peripheral neuropathy', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2023 - 06 June 2023

Ngoi NYL; Sun H; Choi CH; Heong V; Ow SGW; Chay WY; Kim HS; Goss G; Goh JC; Lin M; Lim D; Kim J-W; Friedlander M; Tai BC; Kim K; Tan DSP, 2023, 'Quality of life (QoL) in patients with recurrent ovarian clear cell carcinoma (rOCCC) receiving durvalumab (D) versus physician's choice chemotherapy (PCC) in the randomized phase II MOCCA/APGOT-OV2/GCGS-OV3 trial.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2023 - 06 June 2023

Deva S; Millward M; Friedlander M; Gan HK; Hovarth LG; Lee J-S; Hill A; Sandhu S; Liang L; Shi J; Zhang Y; Shi Y; Ma X; Wu X; Shen Z; Desai J, 2022, 'The combination of hyper-amplification and tumor mutational burden as a pan-cancer biomarker in patients treated with tislelizumab.', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, LA, New Orleans, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), LA, New Orleans, 08 April 2022 - 13 April 2022

Konstantinopoulos P; Gonzalez-Martin A; Cruz F; Friedlander M; Glasspool R; Lorusso D; Marth C; Monk B; Kim J-W; Ajipa O; Su F; Han Y; Matulonis U, 2022, 'EPIK-O/ENGOT-OV61: A PHASE 3, RANDOMIZED STUDY OF ALPELISIB plus OLAPARIB IN PATIENTS WITH NO GERMLINE BRCA MUTATION DETECTED, PLATINUM-RESISTANT OR -REFRACTORY, HIGH-GRADE SEROUS OVARIAN CANCER', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, BMJ PUBLISHING GROUP, pp. A238 - A238, http://dx.doi.org/10.1136/ijgc-2022-igcs.539

Xu X; Wang Y; Bryce N; Tang K; Meagher NS; Kang EY; Kelemen LE; Köbel M; Ramus SJ; Friedlander M; Ford CE; Hardeman EC; Gunning PW, 2021, 'Abstract 1045: Combined targeting of actin/tropomyosin and microtubules underlies a potential treatment strategy of epithelial ovarian cancer with cell-cycle dependent synergy', in Cancer Research, American Association for Cancer Research (AACR), pp. 1045 - 1045, http://dx.doi.org/10.1158/1538-7445.am2021-1045

Xu X; Wang Y; Bryce N; Tang K; Meagher NS; Kang EY; Kelemen LE; Kobel M; Ramus SJ; Friedlander M; Ford CE; Hardeman EC; Gunning PW, 2021, 'Combined targeting of actin/tropomyosin and microtubules underlies a potential treatment strategy of epithelial ovarian cancer with cell-cycle dependent synergy.', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000680263503257&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Wildiers H; Ayoub J-P; Friedlander M; Kaufman B; Arun BK; Han HS; Puhalla SL; Maag D; Feng D; Ratajczak CK; Bach BA; Diéras V, 2021, 'Abstract PS11-03: Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: A subgroup analysis of germline BRCA1 or BRCA2 mutations from the phase 3 BROCADE3 trial', in Cancer Research, American Association for Cancer Research (AACR), http://dx.doi.org/10.1158/1538-7445.sabcs20-ps11-03

Colombo N; Bradley W; Moore K; Gonzalez-Martin A; Scambia G; Oaknin A; Friedlander M; Lowe E; Rowe P; Disilvestro P, 2020, 'MAINTENANCE OLAPARIB IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER AND A BRCA MUTATION: SUBGROUP ANALYSIS BY RISK IN THE PHASE III SOLO1 STUDY', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, BMJ PUBLISHING GROUP, pp. A76 - A77, http://dx.doi.org/10.1136/ijgc-2020-ESGO.130

Friedlander ML; Moore K; Colombo N; Scambia G; Kim B-G; Oaknin A; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; Gonzalez-Martin A; Aghajanian C; Bradley W; Holmes E; Lowe ES; Disilvestro P, 2020, 'Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, pp. S1334 - S1334, presented at ESMO Asia Virtual Congress, ELECTR NETWORK, 20 November 2020 - 22 November 2020, http://dx.doi.org/10.1016/j.annonc.2020.10.228

Meiser B; Gleeson M; Kentwell M; Do J; Nevin S; Taylor N; Barlow-Stewart K; Kirk J; James P; Scott CL; Williams R; Gamet K; Burke J; Murphy M; Antill Y; Pearn A; Pachter N; Ebzery C; Poplawski N; Friedlander M; Tucker K, 2020, 'The development and evaluation of a nationwide training program for oncology health professionals in the provision of genetic testing for ovarian cancer patients', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 62 - 62, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000790145400011&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Swisher EM; Coleman RL; Bookman MA; Brady MF; Fleming GF; Friedlander M; Cunningham MJ; Tewari KS; Edraki B; Moxley K; Mantia-Smaldone GM; Ratajczak C; Dinh MH; Sullivan DM; McClain S; Okubo S; Steffensen KD; Aghajanian C, 2020, 'Safety of veliparib in combination with chemotherapy and as maintenance in front-line ovarian cancer: Results in BRCAm, hrd, and whole populations from the velia trial', in GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS INC ELSEVIER SCIENCE, pp. 20 - 21, http://dx.doi.org/10.1016/j.ygyno.2020.06.040

Banerjee S; Moore KN; Colombo N; Scambia G; Kim B-G; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Oza A; Gonzalez Martin A; Aghajanian C; Bradley W; Holmes E; Lowe ES; DiSilvestro P, 2020, 'Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, pp. S613 - S613, presented at ESMO Virtual Congress, ELECTR NETWORK, 19 September 2020 - 18 October 2020, http://dx.doi.org/10.1016/j.annonc.2020.08.950

Back to profile page